This company has been acquired
Jounce Therapeutics Crecimiento futuro
Future controles de criterios 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Jounce Therapeutics.
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 21.1% |
Tasa de crecimiento de los ingresos | n/a |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | None |
Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
We're A Little Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Rate
Jan 04Here's Why We're Watching Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
Sep 20Here's Why We're A Bit Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
Jun 16We Think Jounce Therapeutics (NASDAQ:JNCE) Can Easily Afford To Drive Business Growth
Feb 23Jounce Therapeutics: A Favorable Risk-Reward Ahead Of Critical 2022 Catalysts
Dec 16News Flash: Analysts Just Made A Dazzling Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Forecasts
Aug 07Jounce Therapeutics: An Under The Radar And Undervalued Biotech
Jul 13Need To Know: Analysts Are Much More Bullish On Jounce Therapeutics, Inc. (NASDAQ:JNCE) Revenues
Jun 16Shareholders May Not Be So Generous With Jounce Therapeutics, Inc.'s (NASDAQ:JNCE) CEO Compensation And Here's Why
Jun 12Jounce Therapeutics EPS beats by $0.01, misses on revenue
May 04We're Hopeful That Jounce Therapeutics (NASDAQ:JNCE) Will Use Its Cash Wisely
May 03Jounce Therapeutics (NASDAQ:JNCE) Shareholders Have Enjoyed An Impressive 163% Share Price Gain
Mar 02News Flash: Analysts Just Made A Sizeable Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Forecasts
Mar 02Enrollment underway in Jounce Therapeutics' early-stage JTX-8064 study in solid tumors
Jan 13Have Insiders Sold Jounce Therapeutics, Inc. (NASDAQ:JNCE) Shares Recently?
Jan 13Jounce Therapeutics: A Potential Roller Coaster
Dec 31A Look At Jounce Therapeutics' (NASDAQ:JNCE) CEO Remuneration
Dec 15En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Jounce Therapeutics no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.
Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.
Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2022 | 82 | -51 | -30 | -29 | N/A |
9/30/2022 | N/A | -132 | -117 | -116 | N/A |
6/30/2022 | N/A | -131 | -82 | -82 | N/A |
3/31/2022 | 25 | -102 | -83 | -83 | N/A |
12/31/2021 | 27 | -91 | -84 | -83 | N/A |
9/30/2021 | 89 | -25 | -16 | -16 | N/A |
6/30/2021 | 89 | -20 | -41 | -41 | N/A |
3/31/2021 | 64 | -44 | -38 | -38 | N/A |
12/31/2020 | 62 | -44 | -28 | -28 | N/A |
9/30/2020 | N/A | -102 | -86 | -86 | N/A |
6/30/2020 | 119 | 22 | -31 | -31 | N/A |
3/31/2020 | 137 | 43 | -31 | -30 | N/A |
12/31/2019 | 148 | 57 | -31 | -30 | N/A |
9/30/2019 | 168 | 77 | -32 | -31 | N/A |
6/30/2019 | 63 | -29 | -83 | -82 | N/A |
3/31/2019 | 65 | -27 | -67 | -66 | N/A |
12/31/2018 | 65 | -27 | -65 | -64 | N/A |
9/30/2018 | 58 | -35 | -71 | -68 | N/A |
6/30/2018 | 62 | -31 | -79 | -75 | N/A |
3/31/2018 | 63 | -30 | -103 | -95 | N/A |
12/31/2017 | 72 | -17 | -106 | -91 | N/A |
9/30/2017 | 79 | -5 | -93 | -79 | N/A |
6/30/2017 | 78 | -1 | 147 | 161 | N/A |
3/31/2017 | 57 | -11 | 165 | 174 | N/A |
12/31/2016 | 37 | -23 | 177 | 180 | N/A |
9/30/2016 | 17 | -38 | N/A | 184 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Insufficient data to determine if JNCE's forecast earnings growth is above the savings rate (2.1%).
Beneficios vs. Mercado: Insufficient data to determine if JNCE's earnings are forecast to grow faster than the US market
Beneficios de alto crecimiento: Insufficient data to determine if JNCE's earnings are expected to grow significantly over the next 3 years.
Ingresos vs. Mercado: Insufficient data to determine if JNCE's revenue is forecast to grow faster than the US market.
Ingresos de alto crecimiento: Insufficient data to determine if JNCE's revenue is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if JNCE's Return on Equity is forecast to be high in 3 years time